Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Patient
 Drug Development
 Resources
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Advertising
 

EquipNet Auction: Sell Your Surplus Equipment on Our Global Marketplace Now!

Our Newest Cartoon Illustrates: "The Biology of Valentines"


Labeling Review Acceptable?

The New Drug Development Process.

Each statement proposed for drug labeling must be justified by data and results submitted in the NDA. The Code of Federal Regulations (CFR) describes labeling requirements in 21 CFR Part 201- Labeling. The labeling is organized in the following sections:





Description Proprietary and established name of drug; dosage form; ingredients; chemical name; and structural formula.
Clinical Pharmacology Summary of the actions of the drug in humans; in vitro and in vivo actions in animals if pertinent to human therapeutics; pharmacokinetics.
Indications and Usage Description of use of drug in the treatment, prevention or diagnosis of a recognized disease or condition.
Contraindications Description of situations in which the drug should not be used because the risk of use clearly outweighs any possible benefit.
Warnings Description of serious adverse reactions and potential safety hazards, subsequent limitation in use, and steps that should be taken if they occur.
Precautions Information regarding any special care to be exercised for the safe and effective use of the drug. Includes general precautions and information for patients on drug interactions, carcinogenesis/mutagenesis, pregnancy rating, labor and delivery, nursing mothers, and pediatric use.
Adverse Reactions Description of undesirable effect(s) reasonably associated with the proper use of the drug.
Drug Abuse/ Dependence Description of types of abuse that can occur with the drug and the averse reactions pertinent to them.
Overdosage Description of the signs, symptoms and laboratory findings of acute overdosage and the general principles of treatment.
Dosage/ Administration Recommendation for usage dose, usual dosage range, and, if appropriate, upper limit beyond which safety and effectiveness have not been established.
How Supplied Information on the available dosage forms to which the labeling applies.

Source: U.S. Food and Drug Administration Center for Drug Evaluation and Research Handbook.


Back to The New Drug Development Process

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

ConnecticutLifeScience.com is owned and published by Info.Resource, Inc.